Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub
Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced endosomal escape technologies, is pleased to announce the opening of its first U.S. laboratory in the Boston-Cambridge area. This strategic expansion marks...
Biotechnology, Pharmaceuticals, Health
2025-06-02 3:15 AM EDT | Defence Therapeutics Inc.
Custom Health Enters into Definitive Agreement to Complete Business Combination with Queue Ventures
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Custom Health, Inc. ("Custom Health"), a technology-enabled healthcare solutions company providing innovative products and services designed to improve the well-being of individuals across North America, has entered into a definitive arrangement agreement dated May 30, 2025 (the "Arrangement Agreement") with Queue...
Technology, Pharmaceuticals, Health
2025-05-30 5:11 PM EDT | Custom Health
Nextleaf Reports Profitable Second Quarter FY25 Results Including Increased Revenue Growth and Positive Net Income Improvement
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), an innovation-driven life science company and licensed cannabis processor, is pleased to announce its financial results for the second quarter of fiscal year 2025, ended March 31...
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2025-05-30 9:00 AM EDT | Nextleaf Solutions Ltd.
Theralase(R) 1Q2025 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses has released the Company's unaudited interim consolidated 1Q2025 financial statements ("Financial...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-30 7:00 AM EDT | Theralase Technologies Inc.
CORRECTION FROM SOURCE: Theralase to Present Groundbreaking Research at ASTRO 2025
This Press Release removes references to preclinical data that has not yet been presented.Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-29 4:30 PM EDT | Theralase Technologies Inc.
New leadership for the Canadian Institute of Actuaries in its 60th year
Ottawa, Ontario--(Newsfile Corp. - May 29, 2025) - Angelita Graham is taking on the role of President of the Canadian Institute of Actuaries (CIA), effective July 1, 2025.Graham, a Fellow of the CIA (FCIA), brings a wealth of experience to the position, having served the Institute since 2008 in multiple...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-29 12:00 PM EDT | Canadian Institute of Actuaries / FR: Institut canadien des actuaires
De nouveaux dirigeants et dirigeantes pour l'Institut canadien des actuaires à l'occasion de sa 60e année
Ottawa, Ontario--(Newsfile Corp. - 29 mai 2025) - Angelita Graham accède à la présidence de l'Institut canadien des actuaires (ICA) à compter du 1er juillet 2025.Graham, Fellow de l'ICA (FICA), apporte une riche expérience à ce poste par le fait d'avoir occupé plusieurs postes bénévoles et de direction au sein...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-29 12:00 PM EDT | Canadian Institute of Actuaries / FR: Institut canadien des actuaires
Neural Therapeutics and Hanf.com Sign Strategic Investment and Option Agreement to Create a Science-Backed Botanical Wellness Leader
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic drugs for mental illnesses related to substance use disorders, and CWE European Holdings Inc. ("CWE"), operating as Hanf.com, a leading German CBD retailer,...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-28 1:52 PM EDT | Neural Therapeutics Inc.
Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name to Unbuzzd Wellness Inc.
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind unbuzzdTM, the scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms, is pleased to announce that it has hired leading audit firm MNP LLP ("MNP") effective...
2025-05-28 8:00 AM EDT | Unbuzzd Wellness Inc.
Theralase to Present Groundbreaking Research at ASTRO 2025
Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is proud to announce promising new preclinical results. The Company's latest...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-28 7:00 AM EDT | Theralase Technologies Inc.
Defence Therapeutics to Attend Bio International Convention in Boston, June 2025
Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced cancer therapeutics and drug delivery technologies, is pleased to announce that its Chief Executive Officer and Chief Operating Officer will be attending the...
Biotechnology, Pharmaceuticals, Health
2025-05-28 3:15 AM EDT | Defence Therapeutics Inc.
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for unmet mental health needs, today announced the finalization of its service agreement with Southern Star Research Pty Ltd ("Southern Star Research"), an award-winning,...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-05-27 7:30 AM EDT | Psyence Biomedical Ltd.
PreveCeutical Welcomes Stephen Glover as Corporate Advisor
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that Steve Glover has been appointed as...
Biotechnology, Pharmaceuticals, Health
2025-05-26 7:00 AM EDT | PreveCeutical Medical Inc.
PreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, following its news releases dated April 2, 2025, April 14, 2025, and April 28, 2025, it has successfully closed the final tranche ("Final Tranche") of...
Biotechnology, Pharmaceuticals, Health
2025-05-22 2:25 PM EDT | PreveCeutical Medical Inc.
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived...
Biotechnology, Pharmaceuticals, Health
2025-05-21 8:30 AM EDT | BioHarvest Sciences Inc.
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that topline results from the chronic cohort of the ongoing Phase 1b/2a study of NVG-291 will be presented as an oral presentation at...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-21 7:30 AM EDT | NervGen Pharma Corp.
Hemostemix Presents at TERMIS 2025, Freiburg, Germany
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology company developing autologous stem cell therapies for cardiovascular diseases, is presenting its groundbreaking clinical trial results and regenerative medicine innovations today at the Tissue Engineering and Regenerative Medicine International Society...
Biotechnology, Pharmaceuticals, Health
2025-05-20 9:00 AM EDT | Hemostemix Inc.
Theralase Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various...
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-05-20 7:00 AM EDT | Theralase Technologies Inc.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-19 7:45 AM EDT | Phio Pharmaceuticals Corp.
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that it has granted 600,000 incentive stock options (the "Options") to directors and employees of the company. The Options are exercisable at a...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-05-16 4:30 PM EDT | NervGen Pharma Corp.